| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2025 | CPIX Cumberland Pharmaceuticals Inc | Jones James53 | Director | Buy | 168 | $5.24 | $880.90 | - | -20.8% | -23.2% | |
| Mar 31, 2025 | CPIX Cumberland Pharmaceuticals Inc | Young Caroline52 | Director | Buy | 74 | $5.18 | $383.66 | - | -20.8% | -23.2% | |
| Mar 27, 2025 | EOLS Evolus, Inc. | Moatazedi David67 | See Remarks | Sell | 6,251 | $12.40 | $77,512.40 | -1.2% | -25.7% | -67.2% | |
| Mar 27, 2025 | VREOF Vireo Growth Inc. | Chicago Atlantic Credit Opportunities, LLC | 10% Owner | Buy | 15,000 | $0.44 | $6,655.50 | +1.9% | - | - | |
| Mar 26, 2025 | HIMS Hims & Hers Health, Inc. | Baird Melissa | Chief Operating Officer | Sell | 67,687 | $34.84 | $2,358,144.87 | -1.7% | +28.7% | -37.5% | |
| Mar 25, 2025 | VREOF Vireo Growth Inc. | Chicago Atlantic Credit Opportunities, LLC | 10% Owner | Buy | 25,750 | $0.43 | $11,131.63 | +2.3% | - | - | |
| Mar 24, 2025 | UTHR United Therapeutics Corp | Thompson Tommy G51 | Director | Sell | 2,500 | $318.80 | $796,990.50 | -22.8% | -10.5% | +66.3% | |
| Mar 24, 2025 | DVAX Dynavax Technologies Corp | Novack David F73 | President &COO | Sell | 10,000 | $14.00 | $140,000.00 | -55.3% | -29.4% | - | |
| Mar 21, 2025 | HIMS Hims & Hers Health, Inc. | Okupe Oluyemi55 | Chief Financial Officer | Sell | 23,118 | $32.41 | $749,175.78 | -15.2% | +84.8% | -36.6% | |
| Mar 21, 2025 | COLL Collegium Pharmaceutical, Inc | Tupper Colleen45 | EVP &Chief Financial Officer | Sell | 7,602 | $30.02 | $228,250.01 | -2.3% | -0.7% | +17.9% | |
| Mar 21, 2025 | COLL Collegium Pharmaceutical, Inc | Dreyer Scott54 | EVP &Chief Commercial Officer | Sell | 20,808 | $30.03 | $624,794.18 | -8.4% | -0.7% | +17.9% | |
| Mar 20, 2025 | KNSA Kiniksa Pharmaceuticals International, Plc | Ragosa Mark | Chief Financial Officer | Sell | 15,944 | $23.11 | $368,465.84 | -40.5% | +17.3% | +93.5% | |
| Mar 20, 2025 | AMLX Amylyx Pharmaceuticals, Inc. | Zeiher Bernhardt G | Director | Buy | 10,000 | $3.70 | $37,005.00 | New | +36.7% | +270.2% | |
| Mar 20, 2025 | VREOF Vireo Growth Inc. | Chicago Atlantic Credit Opportunities, LLC | 10% Owner | Buy | 45,000 | $0.42 | $19,054.50 | +6.8% | - | - | |
| Mar 19, 2025 | UTHR United Therapeutics Corp | Patusky Christopher50 | Director | Sell | 5,000 | $310.72 | $1,553,584.58 | -19.9% | -10.0% | +65.3% | |
| Mar 19, 2025 | ANIP Ani Pharmaceuticals Inc | Davis Krista45 | SVP, Chief Hr Officer | Sell | 1,866 | $65.00 | $121,290.00 | -2.8% | -2.3% | +15.3% | |
| Mar 19, 2025 | KNSA Kiniksa Pharmaceuticals International, Plc | Ragosa Mark | Chief Financial Officer | Sell | 20,343 | $23.10 | $469,923.30 | -30.3% | +21.1% | +97.7% | |
| Mar 18, 2025 | HROW Harrow, Inc. | Opaleye Management Inc.60 | 10% Owner | Sell | 5,000 | $30.01 | $150,055.00 | -3.4% | +16.9% | +27.8% | |
| Mar 18, 2025 | ESPR Esperion Therapeutics, Inc. | Koenig Sheldon L.63 | President And CEO | Sell | 13,047 | $1.50 | $19,622.69 | -0.8% | -25.9% | +58.9% | |
| Mar 18, 2025 | ESPR Esperion Therapeutics, Inc. | Halladay Benjamin | Chief Financial Officer | Sell | 3,535 | $1.48 | $5,242.41 | -0.7% | -25.9% | +58.9% | |
| Mar 18, 2025 | EOLS Evolus, Inc. | Avelar Rui67 | See Remarks | Sell | 27,904 | $13.26 | $369,867.52 | -7.1% | -25.0% | -63.6% | |
| Mar 18, 2025 | EOLS Evolus, Inc. | Moatazedi David67 | See Remarks | Sell | 103,376 | $13.26 | $1,370,248.88 | -16.7% | -25.0% | -63.6% | |
| Mar 18, 2025 | NIKA Nika Pharmaceuticals, Inc | Savov Dimitar Slavchev | CEO, CFO, President | Sell | 2,000,000 | $0.25 | $500,000.00 | -0.4% | - | - | |
| Mar 18, 2025 | EOLS Evolus, Inc. | Beaver Sandra67 | Chief Financial Officer | Sell | 8,996 | $13.26 | $119,242.88 | -4.9% | -25.0% | -63.6% | |
| Mar 18, 2025 | EOLS Evolus, Inc. | Yamagishi-Dressler Tomoko74 | Chief Marketing Officer | Sell | 4,536 | $13.26 | $60,124.68 | -4.5% | -25.0% | -63.6% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.